Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adhesion G protein-coupled receptor E1 (ADGRE1), also known as EMR1, is a member of the adhesion GPCR family characterized by an extended extracellular region containing several EGF-like domains and a seven-transmembrane helix region, linked via a GAIN domain[2][3][4]. It is predominantly expressed on cells of the myeloid lineage: in humans, notably on eosinophils (and minimally on macrophages); in mice, its homolog F4/80 is a widely used marker for tissue-resident macrophages[3][4]. ADGRE1 is involved in cell adhesion, migration, and intercellular signaling, contributing to immune responses, inflammation, and tissue homeostasis[1][2][3][4]. It has roles in mediating macrophage activation and inflammatory signaling, particularly in contexts like metabolic inflammation and chronic immune disorders[1][2]. The receptor is a target for experimental therapies aiming at depleting eosinophils in certain inflammatory and allergic diseases using afucosylated antibodies[3].
Antibody-dependent cell-mediated cytotoxicity against EMR1^+^ (eosinophil) cells
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adhesion G protein-coupled receptor E1 (ADGRE1).